Developments in Nano-scale Drug Delivery Systems Leading to Growing Investment in NDDS in Cancer Therapy Market
Cancer therapy is the biggest question facing the medical fraternity, and has been so for quite a while. Despite the success of processes such as chemotherapy in eradicating cancer, there has always been too much collateral damage for the therapy to be unanimously beneficial. Chemotherapy, as may be widely known, harms healthy human cells in addition to tumorous cells, which necessitates a drawn-out rehabilitation after the cancer treatment. Specialized cancer therapies that don’t affect healthy body tissue are thus becoming the focus of major medicine providers.
A recent discovery in the field of anticancer drug delivery systems was of a sticky microgel that could help anti-cancer drugs stay in the bladder for longer amounts of time than with conventional media. The gel also helps stabilize the release rate of the drugs. The discovery, made by researchers at the University of Reading in August 2015, could become crucial in the global new drug delivery systems market. Bladder cancer has among the highest mortality rates, if not morbidities, of all cancer types, with 50% of about 10,000 patients of bladder cancer dying every year in the U.K. alone. A safe and effective solution to this ailment could revolutionize cancer research, with similar drug delivery systems envisaged against other cancers.
Browse Market Research Report of Novel Drug Delivery Systems (NDDS) in Cancer Therapy Market: http://www.transparencymarketresearch.com/ndds-in-cancer-therapy-market.html
However, the landscape of the global NDDS in cancer therapy market is expected to be dominated by nanomedicine in the coming years, and for good reason.
The Growing Prominence of Nanomedicine in Cancer Drug Delivery
Nanotechnology has emerged on to the global scenario relatively recently, but has made a mark on various walks of human life. In the healthcare industry, the utility of nanoparticles has everything to do with the very fact that gives them their name: they are infinitesimally small.
Since nanoparticles are microscopically small, they are more effective at a given volume than a uniform block of the same medicine. This is due to the exponential increase in the total surface area of the medicine as it is broken down into progressively smaller particles, which allows it to interact with more tumorous cells. This makes nano-scale drug delivery highly effective.
Nano-scale Anticancer Drug Delivery Research Throws up Double Sixes
A promising avenue in the field of nano-scale drug delivery systems in cancer therapy was opened up in May 2014, when a joint research effort by the University of North Carolina and North Carolina State University led to the development of a nano-scale drug delivery system that could deliver a mixture of anti-cancer drugs with higher efficacy than conventional systems.
Browse Market Research Press Release of Novel Drug Delivery Systems (NDDS) in Cancer Therapy Market: http://www.transparencymarketresearch.com/pressrelease/ndds-in-cancer-therapy-market.htm
The therapy comprises two anticancer drugs – doxorubicin (dox) and camptothecin (CPT) – mixed with an aqueous solution of polyethylene glycol (PEG). Both these drugs are hydrophobic, i.e. they repel water, whereas PEG attracts water. This causes the trifecta of solutes to form a daisy-shaped structure, with the dox and CPT molecules enveloped in an outer ring of PEG. Once injected into the bloodstream, PEG helps keep the drug molecules safe till they reach the tumorous cells, whereupon they can set about destroying it with minimal damage to the healthy cells around it. The marvel of nanotechnology is that each of these daisy structures has a diameter of only about 50 nanometers; they are, in more practical terms, about a million times smaller than a pinhead!
According to leading market analysis firm Transparency Market Research, this nano-scale drug delivery system holds promise for the global NDDS in cancer therapy market, which is expected to more than quadruple from 2013 to 2020, rising from a valuation of US$3.6 billion to an estimated US$15.9 billion.